Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives. We are committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
November 16, 2015
Voyager Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares